8-K
filed July 19, 2023, 7:59 PM ET
ticker ELV
CIK 0001156039
earnings
confidence high
sentiment positive
materiality 0.85
Elevance Health Q2 GAAP EPS $7.79, adj. EPS $9.04; raises FY2023 guidance
Elevance Health, Inc.
2023-Q2 EPS reported
$16.10
revenue$85,844,000,000
- Q2 GAAP net income $7.79/sh, adjusted $9.04/sh; operating revenue $43.4B (+12.7% YoY).
- Medical enrollment 48.0M, up 938k YoY; benefit expense ratio improved 70 bps to 86.4%.
- Health Benefits operating gain $2.1B (+21% YoY); Carelon operating gain $632M (+6.8%).
- Raises FY2023 outlook: GAAP EPS >$29.09, adjusted >$32.85.
- Declares Q3 dividend $1.48/sh; repurchased 1.4M shares for $646M in Q2.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Elevance Health, Inc. reported 2023 results: EPS GAAP net income to be greater than $29.09 per share in 2023, and adjusted net income to be greater than $32.85 per share. Guidance raised.
- Period
- 2023
- EPS
- GAAP net income to be greater than $29.09 per share in 2023, and adjusted net income to be greater than $32.85 per share
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
Given the strong performance in the first half of the year and momentum across Elevance Health, we now expect GAAP net income to be greater than $29.09 per share in 2023, and adjusted net income to be greater than $32.85 per share.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Elevance Health, Inc. reported the quarter ended June 30, 2023 results: revenue $43.4 billion, EPS $7.79 per share.
- Period
- the quarter ended June 30, 2023
- Revenue
- $43.4 billion
- EPS
- $7.79 per share
- Result
- reported results
Exact text from the filing
Second quarter GAAP net income was $7.79 per share, including net negative adjustment items of $1.25 per share. Adjusted net income was $9.04* per share. • Operating revenue grew 12.7% year-over-year to $43.4 billion
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.